Hence, there is a growing interest in targeting this receptor in OC, especially with the approval in 2022 of the first ADC utilizing FRα, mirvetuximab soravtansine (MIRV), which is approved for use in FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube, or primary peritoneal cancer. The gene discussed is FOLR1; the disease is peritoneum cancer.